AlgoTherapeutix appoints Edmund Harrigan and Scott Byrd to the…

Paris, 12 April 2021 – Founded in 2018 to design topical treatments for complex pain, AlgoTherapeutix is developing ATX01 in Chemotherapy-Induced Peripheral Neuropathy. Following the recent Series A fundraising and just as ATX01 initiates Clinical Development, AlgoTherapeutix is strengthening its Board of Directors with the appointment of two high-profile independent members.

Edmund P. Harrigan, M.D. has served as a director of Acadia since November 2015.

Ed served as Senior Vice President of Worldwide Safety and Regulatory for Pfizer Inc. from 2012 to 2015.

Ed’s previous executive leadership roles at Pfizer include Senior Vice President, Head of Worldwide Business Development, Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance, Vice President, Head of Neuroscience and Ophthalmology, Vice President of Clinical Development, Therapeutic Area Head, CNS and Pain.

Lire la suite de « AlgoTherapeutix appoints Edmund Harrigan and Scott Byrd to the Board of Directors. » →

ATX01 enters Clinical Development

Paris, Feb 12^th 2021. France-based biotechnology company AlgoTherapeutix, developers of ATX01, an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today that ATX01 was administered to healthy volunteers participating in a Phase I study, designed to establish the product’s local and systemic tolerance in humans and ascertain its limited systemic passage. This is ATX01’s first administration in humans.

In November 2020, AlgoTherapeutix raised 12M€ in a Series A fundraising led by Bpifrance and Omnes Capital, with a view to developing ATX01 through to Phase II in CIPN. The initiation of this Phase I study is the first step in the timely execution of that plan.

Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet:  loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN can prevent patients from walking or using their hands, thus deeply affecting their quality of life.

CIPN is found in over two million patients in the US and Europe, a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.

AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of…

PARIS, France, December 14th 2020 (BUSINESS WIRE)

France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), announced today it has received approval from the ethics committee and the regulatory authority in the Czech Republic to initiate a Phase 1 clinical trial with ATX01. The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021.

“I am thrilled by the entry of ATX01 in clinical development as it represents a great step forward towards providing CIPN patients with a response to the crippling pain they endure.”

Stéphane Thiroloix, Founder & CEO of AlgoTherapeutix

Lire la suite de « AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01 » →

Analgesic Effects of Topical Amitriptyline in Patients with CIPN…

Read more

AlgoTherapeutix raises €12M to take ATX01 into clinical development…

Paris, 24 November 2020 – France-based biotechnology company AlgoTherapeutix, the developer of an innovative topical treatment for chemotherapy-induced peripheral neuropathy (CIPN), has raised €12M in a Series A round led by Bpifrance through its InnoBio 2 fund with co-investor Omnes. Existing and new business angel investors, also significantly participated in this financing round. The proceeds will be used to fund the clinical development of its lead candidate ATX01 up to clinical proof of concept.

Lire la suite de « AlgoTherapeutix raises €12M to take ATX01 into clinical development in chemotherapy-induced peripheral neuropathy » →

AlgoTherapeutix in Business Worldwide’s Top 20 Innovative Companies

https://www.prnewswire.com/news-releases/algotherapeutix-named-among-top-innovative-companies-to-watch-in-2020-by-business-worldwide-magazine-301173816.html

LONDON, Nov. 17, 2020 /PRNewswire/ — Paris based biotech company Algo Therapeutix has made it to Business Worldwide Magazine’s list of Top 20 Innovative Companies to Watch in 2020.

The program is a celebration of trailblazing organizations who are changing the game in their respective industries and altering the corporate landscape. From a wide range of sectors, these companies are at the cutting edge of breakthrough technologies, innovation and modernized business structures. Those included in the list have a shared goal of developing revolutionary products and technology that drives scalable business models and disrupts established industries and markets.

Lire la suite de « AlgoTherapeutix in Business Worldwide’s Top 20 Innovative Companies » →

AlgoTherapeutix featured in Business Worldwide Magazine

AlgoTherapeutix – Developing novel treatments for pain control.

Chemotherapy-Induced Peripheral Neuropathy (CIPN) has always been an iceberg in the ocean of cancer care.  Underestimated and heavily consequential. AlgoTherapeutix, an innovative Paris based biotech focused on complex pain may well melt the iceberg. 

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is an underestimated and devastating condition. Experienced by over 60 per cent of patients undergoing chemotherapy treatments, it ranks among the leading causes of chemotherapy modification or interruption, and is a cause of intense pain for patients.

Lire la suite de « AlgoTherapeutix featured in Business Worldwide Magazine » →

FDA Grants ATX01 Orphan Drug Designation in Erythromelalgia

SURESNES, France- June 8th 2020 -(BUSINESS WIRE)–European biotech AlgoTherapeutix, an innovator in complex pain therapy, today announces the U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary topical amitriptyline) Orphan Drug Designation for the treatment of erythromelalgia.

Lire la suite de « FDA Grants ATX01 Orphan Drug Designation in Erythromelalgia » →

AlgoTherapeutix names Philippe Picaut Chief Scientific Officer

Philippe was previously Sr VP Neurosciences R&D at Ipsen, based in Cambridge (USA). He joins us with a large experience in R&D and business development, in particular in the field of neurology. Philippe is a pharmacist and his qualifications include an MSc in fundamental and applied toxicology, an MSc in anatomopathology, and a diploma of the American Board of Toxicology.

Philippe brings a wealth of expertise as AlgoTherapeutix prepares to raise a Series A to launch ATX01 into clinical development for Chemotherapy-Induced Peripheral Neuropathy.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

• AlgoTherapeutix SAS
• 49 rue des Nouvelles – 92150 Suresnes
• Contact : contact@algotx.com

AlgoTx appoints Etienne Bienfait Fin&Admin Mgr.

As our growth accelerates and we embark on the Series A funding round for the clinical development of ATX01, there could be no better time for Etienne Bienfait to join AlgoTx as Manager of Finance an Administration.

Etienne holds a degree from the University Technical Institute (IUT) in Saint Nazaire and a Research Master in Management from Brest Business School. He has a strong track record in financial controlling at Covage and Bryan Garnier.

AlgoTherapeutix is a French biotech start-up, hosted by the Paris Biotech Santé incubator developing ATX01, a treatment for Chemotherapy-Induced Peripheral Neuropathy.

• AlgoTherapeutix SAS
• 49 rue des Nouvelles – 92150 Suresnes
• Contact : contact@algotx.com